The Technical Analyst
Otonomy Inc [OTIC]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Otonomy Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
-92.64% $0.0085
America/New_York / 11 apr 2023 @ 15:58
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 0.582 mill |
| EPS: | -0.0600 |
| P/E: | -0.142 |
| Earnings Date: | Jul 24, 2023 |
| SharesOutstanding: | 68.53 mill |
| Avg Daily Volume: | 0.877 mill |
| RATING 2023-04-11 |
|---|
| B+ |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Strong Buy | |
| P/E: | Neutral | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/21 | 3/21 | 4/21 | 1/22 | 2/22 | 3/22 | |
| Revenue | n/a | n/a | n/a | n/a | ||
| Gr.Profit | n/a | n/a | n/a | n/a | ||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.142 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.02x |
| Company: PE -0.142 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.0035 - 0.0135 ( +/- 58.82%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-02-15 | Hogan H Michael Iii | Buy | 0 | |
| 2022-12-30 | Weber David Allen | Sell | 91 636 | Common Stock |
| 2022-12-28 | Cayer Paul E | Sell | 40 054 | Common Stock |
| 2022-11-28 | Capps Vickie L | Sell | 42 242 | Common Stock |
| 2022-06-21 | Schroeder Theodore R | Buy | 27 500 | Stock Option (right to buy) |
| INSIDER POWER |
|---|
| -29.78 |
| Last 98 transactions |
| Buy: 7 968 332 | Sell: 3 029 863 |
Forecast:
01:40 - $0.101
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.0085 (-92.64% ) |
| Volume | 1.943 mill |
| Avg. Vol. | 0.877 mill |
| % of Avg. Vol | 221.61 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For OTIC
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
OTIC
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase IIa clinical trials for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties. It also develops OTO-510, an otoprotectant for the prevention of cisplatin-induced hearing loss; OTO-825, a gene therapy for the treatment of congenital hearing loss; and OTO-6XX induces hair cell repair and regeneration for the treatment of severe hearing loss. The company has license agreements with University of California and DURECT Corporation; and strategic collaboration with Applied Genetic Technologies Corporation to develop and commercialize gene therapy for congenital hearing loss. Otonomy, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Latest Press Releases
2022-07-18 07:30:00 - Press Release
Otonomy To Report Second Quarter 2022 Financial Results And Provide Corporate Update
San diego, july 18, 2022 (globe newswire) -- otonomy, inc. (nasdaq: otic), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the second quarter 2022 and provide a corporate update at 4:30 p.m. et on july 25, 2022.
2022-05-02 07:30:00 - Press Release
Otonomy To Report First Quarter 2022 Financial Results And Provide Corporate Update
San diego, may 02, 2022 (globe newswire) -- otonomy, inc. (nasdaq: otic), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the first quarter 2022 and provide a corporate update at 4:30 p.m. et on may 9, 2022.
2022-02-28 07:30:00 - Press Release
Otonomy To Participate In Two Upcoming Investor Conferences
San diego, feb. 28, 2022 (globe newswire) -- otonomy, inc. (nasdaq: otic), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that management will participate in the following virtual investor conference events:
2022-02-17 07:30:00 - Press Release
Otonomy To Report Fourth Quarter And Full Year 2021 Financial Results And Provide Corporate Update
San diego, feb. 17, 2022 (globe newswire) -- otonomy, inc. (nasdaq: otic), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the fourth quarter and full year 2021 and provide a corporate update at 4:30 p.m. et on february 28, 2022.
2021-10-12 07:30:00 - Press Release
Otonomy Announces Publication Of Phase 1/2 Trial Results Showing Tinnitus Improvement In Patients Receiving Oto-313
San diego, oct. 12, 2021 (globe newswire) -- otonomy, inc. (nasdaq: otic), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the publication of its oto-313 phase 1/2 clinical trial results in otology & neurotology, a leading peer-reviewed journal in otolaryngology. these are the first published results to demonstrate a reduction in tinnitus severity for a drug treatment compared to placebo using the tinnitus functional index (tfi), a clinically-validated instrument.
Latest News
2022-11-29 12:27:07 - InvestorPlace
Why Is Otonomy (OTIC) Stock Up 97% Today?
Otonomy (NASDAQ: OTIC ) stock is on the move Tuesday despite a lack of news from the biopharmaceutical company. Instead, it looks like traders have latched onto OTIC stock as the next big short squeeze.
2022-11-15 12:22:22 - PennyStocks
Best Penny Stocks To Buy? 7 To Watch Under $1 Right Now
Penny stocks to buy for under $1 but are they worth the risk? The post Best Penny Stocks To Buy?
2022-10-24 21:21:48 - 24/7 Wall Street
These Were the Five Best and Worst Performing Healthcare Stocks in Q3 2022
The healthcare industry is now starting to shift its focus away from the coronavirus pandemic to work on its core activities.
2022-07-25 20:18:13 - Seeking Alpha
Otonomy, Inc. (OTIC) CEO Dave Weber on Q2 2022 Results - Earnings Call Transcript
Otonomy, Inc. (NASDAQ:OTIC ) Q2 2022 Earnings Conference Call July 25, 2022 4:30 PM ET Company Participants Robert Uhl - Managing Director, ICR Westwicke Dave Weber - Chief Executive Officer, President and Board Member Paul Cayer - Chief Financial and Business Officer Conference Call Participants Ken Cacciatore - Cowen and Company Chris Raymond - Piper Sandler Francois Brisebois - Oppenheimer and Company Oren Livnat - H.C. Wainwright & Co. Operator Good day, and thank you for standing by.
2022-07-18 07:30:00 - GlobeNewsWire
Otonomy to Report Second Quarter 2022 Financial Results and Provide Corporate Update
SAN DIEGO, July 18, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the second quarter 2022 and provide a corporate update at 4:30 p.m. ET on July 25, 2022.
2022-05-09 22:21:02 - Seeking Alpha
Otonomy, Inc. (OTIC) CEO Dr. David Weber on Q1 2022 Results - Earnings Call Transcript
Otonomy, Inc. (NASDAQ:OTIC ) Q1 2022 Earnings Conference Call May 9, 2022 4:30 PM ET Company Participants Robert Uhl - IR David Weber - President, CEO and Director Paul Cayer - Chief Financial & Business Officer Conference Call Participants Ken Cacciatore - Cowen Chris Raymond - Piper Sandler Pete Stavropoulos - Cantor Fitzgerald Francois Brisebois - Oppenheimer Operator Good day, and thank you for standing by. Welcome to the Otonomy First Quarter 2022 Financial Results Conference Call.
2022-05-02 07:30:00 - GlobeNewsWire
Otonomy to Report First Quarter 2022 Financial Results and Provide Corporate Update
SAN DIEGO, May 02, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the first quarter 2022 and provide a corporate update at 4:30 p.m. ET on May 9, 2022.
2022-04-04 12:23:49 - Seeking Alpha
Otonomy: Hearing Loss And Tinnitus Data In 2022
2022-02-28 07:30:00 - GlobeNewsWire
Otonomy to Participate in Two Upcoming Investor Conferences
SAN DIEGO, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that management will participate in the following virtual investor conference events:
2022-02-17 07:30:00 - GlobeNewsWire
Otonomy to Report Fourth Quarter and Full Year 2021 Financial Results and Provide Corporate Update
SAN DIEGO, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the fourth quarter and full year 2021 and provide a corporate update at 4:30 p.m. ET on February 28, 2022.